• Mashup Score: 25
    COVID-19 Guideline, Part 1: Treatment and Management - 3 year(s) ago

    COVID-19 is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, IDSA felt the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and…

    Source: www.idsociety.org
    Categories: Infectious Disease, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of IDSAInfo
      IDSAInfo

      IDSA has released new guideline recommendations on the use of #bamlanivimab among hospitalized patients and #casirivimab/#imdevimab among ambulatory patients for the Treatment & Management of Patients with COVID-19. #COVID19Guidelines 📄https://t.co/SK6zyOJKtO https://t.co/jxE6rLy67l

  • Mashup Score: 3
    FDA authorizes emergency use of casirivimab, imdevimab for COVID-19 - 3 year(s) ago

    The FDA granted emergency use authorization for the monoclonal antibodies casirivimab and imdevimab to be administered together intravenously for the treatment of mild to moderate COVID-19.According to a press release, this EUA pertains to adults and children aged 12 years and older with positive SARS-CoV-2 viral test results who weigh 88 pounds or more and are at high risk for progressing to

    Source: www.healio.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GoHealio
      GoHealio

      The @US_FDA granted emergency use authorization for the @Regeneron monoclonal antibodies #casirivimab & #imdevimab to be administered together intravenously for treatment of mild to moderate #COVID-19 https://t.co/bQznLW7CYf #coronavirus #COVID19 #coronaviruspandemic #medtwitter https://t.co/EIcS4wTsff